Diary and Patient-Reported Outcomes in Patients with Severe Overactive Bladder Switching from Tolterodine Extended Release 4 mg/day to Solifenacin Treatment: An Open-Label, Flexible-Dosing, Multicentre Study

Author: Swift Steven E.  

Publisher: Adis International

ISSN: 1173-2563

Source: Clinical Drug Investigation, Vol.29, Iss.5, 2009-01, pp. : 305-316

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract